Clinical trial
Celecoxib in Treating Patients With Bladder Cancer
NCT00006124 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006124 |
|---|---|
| Title | Celecoxib in Treating Patients With Bladder Cancer |
| Official title | Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Recurrent Bladder Cancer |
| Intervention type | Drug |
| Interventions | celecoxib, placebo |
| Enrollment | 152 |
| Start date | Jun 1, 2000 |
| Primary completion | Mar 1, 2006 |
| Completion | Apr 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 13, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: